Whole body MRI and PET/CT in haematological malignancies

Abstract The usefulness of whole body magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT) in haematological malignancies is reviewed. PET/CT combining functional and anatomical information is currently a valuable tool in the management of patients with lymphoma, especially in the assessment of early treatment response. MRI is advantageous in evaluating bone marrow involvement and therefore plays an important role in clinical decision making for patients with myeloma. The development of whole body functional MR studies is underway and can potentially complement the PET/CT for better patient care.

[1]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[2]  C. Copie-Bergman,et al.  Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. , 2007, Haematologica.

[3]  B. Barlogie,et al.  Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Gerhard Glatting,et al.  Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience. , 2007, Radiology.

[6]  R. Wahl,et al.  Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  B. Line,et al.  Comparison of imaging with FDG PET/CT with other imaging modalities in myeloma , 2006, Skeletal Radiology.

[8]  S. Schoenberg,et al.  Whole-body MRI and PET-CT in the management of cancer patients , 2006, European Radiology.

[9]  M. Mulligan,et al.  PET/CT and MR imaging in myeloma , 2006, Skeletal Radiology.

[10]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[11]  E. Kotter,et al.  Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey , 2006, European Radiology.

[12]  Yuji Nakamoto,et al.  Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. , 2005, Radiology.

[13]  M. O'Doherty,et al.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Emmanuel Itti,et al.  [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.

[15]  M. Reiser,et al.  Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.

[16]  S. Schoenberg,et al.  Whole-body MR imaging of bone marrow. , 2005, European journal of radiology.

[17]  M. Reiser,et al.  Neovascularization of bone marrow in patients with diffuse multiple myeloma , 2004, Cancer.

[18]  M. Morris,et al.  Imaging therapeutic response in human bone marrow using rapid whole‐body MRI , 2004, Magnetic resonance in medicine.

[19]  P. Babyn,et al.  Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children , 2004, European Radiology.

[20]  T. Takahara,et al.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. , 2004, Radiation medicine.

[21]  J. Debatin,et al.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. , 2003, JAMA.

[22]  P. Gaulard,et al.  Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.

[23]  G. Morgan,et al.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.

[24]  A. Waxman,et al.  Whole-body (18)F-FDG PET identifies high-risk myeloma. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M. Dietel,et al.  Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma , 2000, Annals of Hematology.

[26]  M. Dimopoulos,et al.  Multiple myeloma: MR patterns of response to treatment. , 1994, Radiology.

[27]  A. Rahmouni,et al.  MR appearance of multiple myeloma of the spine before and after treatment. , 1993, AJR. American journal of roentgenology.